Comprehensive Genomic Analysis of Patients with Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings from the BFAST Database of a Single Center in Taiwan

Medicine, Medical Laboratory Science, Hematology, Oncology, Life Sciences, Immunology, Genetics,
Non-Small-Cell Lung Cancer   Blood Test   Circulating Tumor DNA   Genomic Analysis   BFAST   Actionable Mutations  

Latest Research in Lung Cancer Genomics: Analysis of Circulating Tumor DNA Detection in Non-Small Cell Lung Cancer Background and Motivation In recent years, the treatment of non-small cell lung cancer (NSCLC) has seen significant changes due to the success of targeted therapies. The National Comprehensive Cancer Network guidelines recommend extens...

Epithelial−Mesenchymal Transition Induced by Tumor Cell-Intrinsic PD-L1 Signaling Predicts a Poor Response to Immune Checkpoint Inhibitors in PD-L1-High Lung Cancer

Medicine, Rheumatology and Immunology, Respiratory System, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
PD-L1   Epithelial-Mesenchymal Transition   Non-Small-Cell Lung Cancer   Immune Checkpoint Inhibitors   Biomarkers   Tumor Progression  

Tumor Cell-Intrinsic PD-L1 Signaling Induces Epithelial-Mesenchymal Transition (EMT) Predicting Poor Response to Immune Checkpoint Inhibitors in PD-L1 High-Expressing Lung Cancer Research Background and Motivation In cancer immunotherapy, Programmed Death Ligand-1 (PD-L1) inhibits immune responses by binding to Programmed Death-1 (PD-1) receptors o...